证券代码：300015 股票简称：爱尔眼科 公告编号：2025-046 爱尔眼科医院集团股份有限公司 关于2021年限制性股票激励计划首次授予部分第四个解除限售期 解除限售条件成就但股票暂不上市的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1、本次限制性股票解除限售的条件达成之日为 2025 年 6 月 15 日； 2、本次符合解除限售条件的激励对象共计 4,418 名，均满足 100%解除限售条件，可解除 限售的限制性股票数量为 19,390,095 股，占公司目前总股本的 0.2079%； 3、根据公司《2021 年限制性股票激励计划（草案）》所有激励对象承诺，自每个解除限 售的条件达成之日起 6 个月内，其所持有的当批次解除限售的全部限制性股票不得转让。因此 公司申请本次解除限售的限制性股票暂不上市，继续禁售至 2025 年 12 月 14 日。后续，公司将 向深圳证券交易所、中国证券登记结算有限责任公司深圳分公司申请办理本次解除限售股票的 手续。届时公司将另行公告，敬请投资者注意。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 ...

湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2021 年限制性股票激励计划首次授予部分 第四个解除限售期解除限售条件成就相关事项 的法律意见书 2025 年 6 月 致：爱尔眼科医院集团股份有限公司 湖南启元律师事务所（以下简称"本所"）接受爱尔眼科医院集团股份有限公 司（以下简称"公司""爱尔眼科"）的委托，作为公司2021年限制性股票激励计 划项目（以下简称"本次激励计划""激励计划"）专项法律顾问为公司本次激励 计划提供专项法律服务。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）及中国证券监督管理委员会（以 下简称"中国证监会"）发布的《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、深圳证券交易所发布的《深圳证券交易所创业板上市公司自律监 管指南第1号——业务办理》（以下简称"《监管指南》"）、《深圳证券交易所 创业板股票上市规则》（以下简称"《上市规则》"）等现行法律、法规和规范 性文件以及《爱尔眼科医院集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，按照律师行业公认的业务标准、道德规范和勤勉 ...

Core Viewpoint - The company emphasizes that chaotic price wars are detrimental to the sustainable development of the medical industry and will harm patient rights [1][2]. Group 1: Company Insights - Aier Eye Hospital has seen a steady recovery in the average price of refractive surgeries since last year, indicating a gradual industry clearing where demand is shifting towards reputable hospitals [1]. - The company plans to launch upgraded surgical techniques in 2024, including All-Laser LASIK and ICLV5 lenses, to meet diverse patient needs [1]. - Aier Eye Hospital's overseas business revenue is projected to account for approximately 12.5% in 2024, reflecting a 1% increase from the previous year, with plans for further expansion in Europe and Southeast Asia [3]. Group 2: Industry Trends - The aging population is driving demand for age-related eye disease treatments, particularly for presbyopia, which is currently under-recognized in China [2]. - The company anticipates significant growth potential in presbyopia treatment, similar to trends observed in developed countries [2]. - The company's profitability is expected to improve as patient volumes increase, benefiting from economies of scale and reduced sales expense ratios [3].

Core Viewpoint - The ophthalmology industry has experienced a price war in refractive surgery over the past couple of years, but the situation is expected to improve starting from Q3 2024 due to brand reputation and advancements in surgical techniques [1] Company Summary - Aier Eye Hospital (300015) indicated that the average transaction price for refractive surgeries is stabilizing and expected to rise continuously from Q3 2024 onwards, benefiting from its brand reputation and the iterative upgrade of surgical methods [1]

证券代码：300015 证券简称：爱尔眼科 爱尔眼科医院集团股份有限公司投资者关系活动记录表 编号：2025-002 投资者关系 活动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名 称及人员姓 名 易方达基金：杨桢霄、王俊杰、朱明新； 景顺长城基金：刘彦春、周寒颖、王玉、邓敬东、张欢、谢燕萍； 兴业证券：黄翰漾； 国海证券：李明、蒲美鑫、王宇飞。 时间 2025 年 6 月 10 日– 6 月 11 日 地点 公司会议室 上市公司接 待人员姓名 董事长：陈邦 董事会办公室工作人员 投资者关系 活动主要内 容介绍 一、过去的一两年，眼科行业出现了屈光手术"价格战"现象， 目前情况如何？ 答：从 2024 年 3 季度开始，得益于品牌口碑以及术式迭代 升级，公司屈光手术客单价持续企稳回升。公司屈光技术始终保 持国际同步、国内领先，同时坚持倡导"适合的才是最好的"基 本理念，术式种类日益丰富齐全，为患者提供个性化、精准化的 医疗服务。2024 年，公司陆续推出全光塑、全飞秒 4.0 等升级 术式，目前新术式按计划推广 ...

Group 1 - The core viewpoint of the article highlights that Aier Eye Hospital's stock closed at 12.47 yuan, down 1.42%, with a rolling PE ratio of 31.38 times and a total market capitalization of 116.288 billion yuan [1] - The average PE ratio for the medical services industry is 41.83 times, with a median of 45.41 times, placing Aier Eye Hospital at the 22nd position in the industry ranking [1] - As of March 31, 2025, Aier Eye Hospital had 347,329 shareholders, a decrease of 31,805 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Aier Eye Hospital's main business includes diagnosis and surgical services for various eye diseases, with key products being refractive projects, cataract projects, anterior segment projects, posterior segment projects, and vision services [1] - In the latest quarterly report for Q1 2025, the company achieved an operating revenue of 6.026 billion yuan, a year-on-year increase of 15.97%, and a net profit of 1.050 billion yuan, up 16.71%, with a gross profit margin of 48.02% [1]

Core Viewpoint - The ChiNext 50 Index is experiencing a strong upward trend, with significant gains in constituent stocks, indicating a positive market sentiment towards growth-oriented companies in the ChiNext sector [2][3]. Group 1: Index Performance - As of June 9, 2025, the ChiNext 50 Index (399673) rose by 1.41%, with notable increases in stocks such as Tianfu Communication (300394) up 7.03% and Tiger Medical (300347) up 5.68% [2]. - The ChiNext 50 ETF (159367) also saw a rise of 1.47%, with a latest price of 0.97 yuan, and a cumulative increase of 2.26% over the past week [2]. Group 2: Trading and Liquidity - The ChiNext 50 ETF recorded a turnover rate of 0.59% during the trading session, with a transaction volume of 24.10 thousand yuan [2]. - Over the past year, the average daily trading volume for the ChiNext 50 ETF was 538.65 thousand yuan [2]. Group 3: Return and Drawdown - Since its inception, the ChiNext 50 ETF has achieved a maximum monthly return of 3.14%, with an average monthly return of 1.79% during rising months [2]. - The relative drawdown since inception is 1.34% compared to its benchmark [2]. Group 4: Fee Structure - The management fee for the ChiNext 50 ETF is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [2]. Group 5: Valuation Metrics - The ChiNext 50 Index is currently valued at a historical low with a price-to-book (PB) ratio of 4.21, which is below 81.19% of the time over the past five years, indicating attractive valuation [3]. - The index comprises 50 stocks with high liquidity and market capitalization, reflecting the overall performance of well-known companies in the ChiNext market [3]. Group 6: Top Holdings - As of May 30, 2025, the top ten weighted stocks in the ChiNext 50 Index account for 65.6% of the index, including Ningde Times (300750) at 24.47% and Dongfang Wealth (300059) at 10.62% [3][5].

Aier Eye Hospital AIC 2025: Premiumisation of refractive business; aiming to improve 2025 margins 更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha abc 3 June 2025 First Read 2025 targets: Improve margins and ASPs for refractive business We invited Aier to participate in the UBS 2025 AIC. Given macro uncertainties, the company did not provide guidance for 2025, but highlighted its targets of improving margins and ASPs for refractive business. The performance of the refractive and optometry business was lackluster in April, w ...

Group 1 - The "Eye Care Cup" second national children's painting collection activity was officially launched on June 6, aiming to encourage children to express their creativity while promoting eye health awareness [1][3] - The first edition of the event received over 157,000 entries from more than 10 provinces, showcasing children's imagination and artistic skills [3] - This year's event has expanded its scope and content, incorporating scientific education elements and encouraging participation in eye health-themed children's dramas [3][4] Group 2 - The theme for this year's activity is "Guarding the Window of the Soul, Chasing the Light of Dreams," focusing on eye care and vision protection for children aged 5-18 [4] - The overall myopia rate among children and adolescents in China is currently at 52.7%, with significant rates among different educational levels: 35.6% for primary school students, 71.1% for middle school students, and 80.5% for high school students [5] - The prevention of myopia is recognized as a long-term societal responsibility, with the government integrating it into national health strategies and educational planning [5][6] Group 3 - Experts emphasize that 80% of myopia cases stem from poor eye habits, such as excessive screen time and close reading, highlighting the importance of increasing outdoor activities [6] - Aier Eye Hospital has developed a comprehensive myopia prevention system and innovative technologies for myopia correction, including wearable devices and AI-assisted tools [6][7] - The organization has also launched various educational initiatives and activities to promote eye health awareness among children and adolescents [7]

Core Viewpoint - The article emphasizes the investment strategy of "buying primary assets in the secondary market," which is a value investment approach that can yield excess returns by identifying undervalued stocks that exhibit characteristics of primary market investments [2][5]. Group 1: Concept of "Buying Primary Assets in the Secondary Market" - The primary market serves as a "incubation ground" for capital, where investors support companies' growth from inception, while the secondary market acts as a "trading venue" where stock prices can be distorted by emotions and external factors [4][5]. - This strategy involves identifying companies engaged in value-creating activities such as technological research, mergers and acquisitions, and market expansion, but whose stock prices do not yet reflect their long-term value [5][6]. Group 2: Identifying Investment Opportunities - Key indicators for identifying suitable investments include significant asset restructuring, major technological breakthroughs, and the exploration of new business avenues [7]. - Investors should be cautious of "hype-driven" stocks that lack substantial investment in genuine growth initiatives, distinguishing between companies with real financial commitments and those merely riding trends [7]. Group 3: Market Mispricing and Management Insight - Look for stocks with price-to-earnings (PE) ratios below 70% of the industry average or market capitalizations below their replacement costs, as these may indicate mispricing [8]. - Assess management's "primary market thinking" by examining their professional backgrounds and the proportion of shares they hold, with a higher ownership stake (over 30%) suggesting stronger alignment of interests [9]. Group 4: Conclusion and Investment Philosophy - The essence of the primary market is "value discovery," while the secondary market offers opportunities for "price negotiation." The intersection of these two aspects can lead to excess returns [11]. - When observing a company investing heavily in research and development or acquiring assets at low prices while its stock price declines, it may present an opportunity to "buy primary assets in the secondary market" [11].